title: Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study.
abstract: OBJECTIVE
  To assess the risk of adverse perinatal events of vaccination of pregnant women with an MF59 adjuvanted vaccine.
  
  
  METHODS
  Cross sectional multicentre study.
  
  
  METHODS
  49 public hospitals in major cities in Argentina, from September 2010 to May 2011.
  
  
  METHODS
  30,448 mothers (7293 vaccinated) and their 30,769 newborns.
  
  
  METHODS
  Primary composite outcome of low birth weight, preterm delivery, or fetal or early neonatal death up to seven days postpartum.
  
  
  RESULTS
  Vaccinated women had a lower risk of the primary composite outcome (7.0% (n=513) v 9.3% (n=2160); adjusted odds ratio 0.80, 95% confidence interval 0.72 to 0.89). The propensity score analysis showed similar results. Adjusted odds ratios for vaccinated women were 0.74 (0.65 to 0.83) for low birth weight, 0.79 (0.69 to 0.90) for preterm delivery, and 0.68 (0.42 to 1.06) for perinatal mortality. These findings were consistent in further subgroup analysis. No significant differences in maternal outcomes were found.
  
  
  CONCLUSIONS
  This large study using primary data collection found that MF59 adjuvanted A/H1N1 influenza vaccine did not result in an increased risk of adverse perinatal events and suggested a lower risk among vaccinated women. These findings should contribute to inform stakeholders and decision makers on the prescription of vaccination against influenza A/H1N1 in pregnant women.
authors: Institute for Clinical Effectiveness and Health Policy, Emilio Ravignani 2024, Buenos Aires, Argentina. frubinstein@iecs.org.ar
authors: F
authors: F
authors: Rubinstein
authors: P
authors: P
authors: Micone
authors: A
authors: A
authors: Bonotti
authors: V
authors: V
authors: Wainer
authors: A
authors: A
authors: Schwarcz
authors: F
authors: F
authors: Augustovski
authors: A
authors: A
authors: Pichon Riviere
authors: A
authors: A
authors: Karolinski
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D007252:Influenza Vaccines / Q000627:therapeutic use*; D007251:Influenza, Human / Q000517:prevention & control*; D016015:Logistic Models; D011136:Polysorbates / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control*; D011256:Pregnancy Outcome; D011261:Pregnancy Trimester, First; D057216:Propensity Score; D013185:Squalene / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; C558220:focetria; D013185:Squalene
references: PLoS One. 2010 Oct 05;5(10):
references: 20957195
references: Med J Aust. 2010 Oct 4;193(7):405-7
references: 20919972
references: JAMA. 2010 Dec 1;304(21):2360-1
references: 21119083
references: Vaccine. 2010 Nov 3;28(47):7455-6
references: 20832495
references: Obstet Gynecol. 2010 Oct;116(4):949-955
references: 20859160
references: BMJ. 2012 May 02;344:e3091
references: 22551717
references: Vaccine. 2010 Jul 26;28(33):5389-97
references: 20542072
references: Am J Public Health. 2012 Jun;102(6):e33-40
references: 22515877
references: Am J Perinatol. 1986 Jul;3(3):179-82
references: 3718637
references: Vaccine. 2011 Feb 1;29(6):1180-4
references: 21172382
references: Vaccine. 2011 Feb 4;29(7):1357-8
references: 21185422
references: N Engl J Med. 2010 Jan 7;362(1):45-55
references: 20032320
references: Vaccine. 2010 Feb 17;28(7):1877-80
references: 19969117
references: Euro Surveill. 2010 Mar 25;15(12):
references: 20350496
references: BMJ. 2012 May 02;344:e2794
references: 22551713
references: JAMA. 2012 Jul 11;308(2):165-74
references: 22782418
references: N Engl J Med. 2009 Aug 13;361(7):674-9
references: 19564633
references: N Engl J Med. 2009 Dec 17;361(25):2424-35
references: 19745215
references: BMJ. 2011 Jun 14;342:d3214
references: 21672992
references: Med Clin (Barc). 2010 Oct 16;135(12):543-5
references: 20673677
references: J Infect Dis. 2011 May 1;203(9):1301-8
references: 21459817
references: Health Technol Assess. 2010 Dec;14(55):1-82
references: 21208547
references: N Engl J Med. 2010 Jan 7;362(1):27-35
references: 20032319
references: MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1-62
references: 20689501
references: CMAJ. 2007 Feb 13;176(4):463-8
references: 17296958
references: Zh Mikrobiol Epidemiol Immunobiol. 2010 Jul-Aug;(4):114-7
references: 20799404
references: BMJ. 2010 Mar 18;340:c1279
references: 20299694
references: Am J Obstet Gynecol. 2011 Feb;204(2):146.e1-7
references: 20965490
references: Clin Infect Dis. 2010 Mar 1;50(5):686-90
references: 20100064
references: Vaccine. 2011 Jan 10;29(3):370-7
references: 21075164
references: Obstet Gynecol. 2010 Oct;116(4):1006-1007
references: 20859176
references: Vaccine. 2011 Feb 24;29(10):1941-7
references: 21236235
references: Vaccine. 2010 Nov 29;28(51):8157-61
references: 20937310
references: Clin Infect Dis. 2010 Dec 15;51(12):1355-61
references: 21058908
references: Obstet Gynecol. 2010 Apr;115(4):717-726
references: 20308830
references: Epidemiol Rev. 2006;28:47-53
references: 16731574
references: Am J Epidemiol. 1998 Dec 1;148(11):1094-102
references: 9850132
references: Arch Pediatr Adolesc Med. 2011 Feb;165(2):104-11
references: 20921345
references: Am J Obstet Gynecol. 2012 Sep;207(3):177.e1-8
references: 22939717
references: Lancet. 2009 Aug 8;374(9688):451-8
references: 19643469